Mutations in the TERT promoter are among the most common genetic alterations in a variety of cancers, such as melanoma, glioblastoma, and bladder cancer. These mutations typically create new binding sites for transcription factors, leading to increased TERT expression and telomerase activity. This hyperactivation of telomerase enables cancer cells to maintain their telomeres, thereby supporting indefinite cell proliferation.
